National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

integrin-targeted immunoconjugate IMGN388
An immunoconjugate consisting of an anti-integrin monoclonal antibody covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Integrin-targeted immunoconjugate IMGN388 binds to tumor cell surface integrins; upon internalization, the DM4 moiety is released from the immunoconjugate, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in inhibition of cell division and cell growth of integrin-expressing tumor cells. Integrins, a class of transmembrane cell surface receptors, link the extracellular matrix (ECM) to intracellular signaling pathways that control cell proliferation and differentiation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:IMGN388



Previous:Innohep, INO-1001, inosine dialdehyde, inositol, inotuzumab ozogamicin
Next:interferon alfacon-1, interleukin-12 gene, interleukin-2 gene, interleukin-2 liposome, IntraDose

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov